Platelet Transfusion: And Update on Challenges and Outcomes

Pilar Solves Alcaina, Pilar Solves Alcaina

Abstract

Platelet transfusion is a common practice in onco-hematologic patients for preventing or treating hemorrhages. Platelet concentrates can be transfused with therapeutic or prophylactic purposes. With the aim to help clinicians to take the decisions on platelet transfusion, some guidelines have been developed based on the current scientific evidence. However, there are some controversial issues and available scientific evidence is not enough to solve them. There is little information about what is the best platelet product to be transfused: random platelets or single donor apheresis platelets, and plasma-suspended or additive solution suspended platelets. Platelets are often transfused without respecting the ABO compatibility, but influence of this practice on platelet transfusion outcome is not well established. In the prophylactic platelet transfusion set there are some questions unsolved as the platelet threshold to transfuse prior to specific procedures or surgery, and even if platelet transfusion is necessary for some specific procedures as autologous hematopoietic stem cell transplantation. A challenging complication raised from multiple platelet transfusions is the platelet transfusion refractoriness. The study and management of this complication is often disappointing. In summary, although it is a widespread practice, platelet transfusion has still many controversial and unknown issues. The objective of this article is to review the current evidence on platelet transfusion practices, focusing on the controversial issues and challenges.

Keywords: platelet transfusion; platelet transfusion refractoriness; prophylactic transfusion.

Conflict of interest statement

The author reports no conflicts of interest in this work.

© 2020 Solves Alcaina.

References

    1. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev. 2004;18:149–165. doi:10.1016/S0268-960X(03)00057-2
    1. Informe hemovigilancia; 2017. Available from: . Accessed January 15, 2020.
    1. Ellingson KD, Sapianzo MRP, Haass KA, et al. Continue decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;27:1588–1598. doi:10.1111/trf.14165
    1. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7(2):132–150. doi:10.2450/2009.0005-09
    1. McCullough J. Overview of platelet transfusion. Semin Hematol. 2010;47(3):235–242. doi:10.1053/j.seminhematol.2010.04.001
    1. Cid J, Harm SK, Yazer MH. Platelet transfusion: the art and science of compromise. Transfus Med Hemother. 2013;40:160–171. doi:10.1159/000351230
    1. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205–213. doi:10.7326/M14-1589
    1. SETS. Guía sobre la transfusión de componentes sanguíneos y derivados plasmáticos. SETS, Ed, 5; 2015.
    1. Nahirniak S, Slichter SJ, Tanael S, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfus Med Rev. 2015;29:3–13. doi:10.1016/j.tmrv.2014.11.004
    1. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology. 2017;1:172–178. doi:10.1182/asheducation-2007.1.172
    1. Scourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176:365–394. doi:10.1111/bjh.14423
    1. Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(3):283–299. doi:10.1200/JCO.2017.76.1734
    1. Stanworth SJ, Navarrete C, Estcourt L, et al. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297–305. doi:10.1111/bjh.13597
    1. Ness PM, Campbell-Lee SA. Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol. 2001;8(6):392–396. doi:10.1097/00062752-200111000-00013
    1. Whitaker BI, Green J, King MR, et al. The 2007 Nationwide Blood Collection and Utilization Survey Report. Department of Health and Human Services, Washington, DC; 2008. Available from: . Accessed December31, 2019.
    1. Storch EK, Custer BS, Jacobs MR, Menitove JE, Mintz PD. Review of current transfusion therapy and blood banking practices. Blood Rev. 2019;25:100593. doi:10.1016/j.blre.2019.100593
    1. Andreu G, Vasse J, Hervé F, Tardivel R, Semana G. Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients. Transfus Clin Biol. 2007;14(1):100–106. doi:10.1016/j.tracli.2007.03.009
    1. Xiao W, Tormey CA, Capetillo A, Maitta RW. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sang. 2013;105:334–340. doi:10.1111/vox.12063
    1. Vamvakas EC. Risk-reduction strategies for platelet transfusion in the United States. Sci World J. 2011;11:624–640. doi:10.1100/tsw.2011.60
    1. Vamvakas EC. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion. 2009;49:2743–2758. doi:10.1111/j.1537-2995.2009.02338.x
    1. López-Menchero C, Alvarez M, Fernández P, Guzmán M, Ortiz-de-Salazar MI, Arbona C. Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the region of Valencia, Spain, during a 15-year period (2003-2017). Blood Transfus. 2019;7:1–12. doi:10.2450/2019.0058-19
    1. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861–1869. doi:10.1056/NEJM199712253372601.
    1. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–613. doi:10.1056/NEJMoa0904084
    1. Triulzi DJ, Assmann SF, Strauss RG, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood. 2012;7:8553–8561. doi:10.1182/blood-2011-11-393165
    1. Singh RP, Marwaha N, Malhotra P, Dash S. Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet concentrate (BC-PC) and apheresis-PC methods. Asian J Transfus Sci. 2009;3(2):86–94. doi:10.4103/0973-6247.53882
    1. Pietersz RN. Pooled platelet concentrates: an alternative to single donor apheresis platelets? Transfus Apher Sci. 2009;41(2):115–119. doi:10.1016/j.transci.2009.07.003
    1. Weinstein R, Simard A, Ferschke J, et al. Prospective surveillance of D- recipients of D+ apheresis platelets: alloimmunisation against D is not detected. Transfusion. 2015;55:1327–1330. doi:10.1111/trf.12972
    1. Molnar R, Johnson R, Sweat LT, Geiger TL. Absence of alloimmunization in D– pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion. 2002;42:177–182. doi:10.1046/j.1537-2995.2002.00015.x
    1. Villalba A, Santiago M, Freiria C, et al. Anti-D alloimmunization after RhD-positive platelet transfusion in RhD-negative women under 55 years diagnosed with acute leukemia: results of a retrospective study. Transfus Med Hemother. 2018;45(3):162–166. doi:10.1159/000488804
    1. O´Brian KL, Hasper RL, Uhl L. Anti-D alloimmunization after D-incompatible platelet transfusions: a 14-year single-institution retrospective review. Transfusion. 2014;54:650–654. doi:10.1111/trf.12341
    1. Cid J, Yazer MH, Lozano M. Platelet transfusion and respecting patient D type. Curr Opin Hematol. 2015;22(6):540–546. doi:10.1097/MOH.0000000000000185
    1. Cooling LL, Kelly K, Barton J, Hwang D, Koerner TA, Olson JD. Determinants of ABH expression on human blood platelets. Blood. 2005;15:3356–3364. doi:10.1182/blood-2004-08-3080
    1. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Asher RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood. 2000;15:1574–1581. doi:10.1182/blood.V96.4.1574
    1. Lozano M, Heddle N, Williamson LM, et al. Practices associated with ABO-incompatible platelets transfusions: a BEST collaborative international survey. Transfusion. 2010;50:1743–1748. doi:10.1111/j.1537-2995.2010.02642.x
    1. Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K. ABO-identical versus nonidentical platelet transfusión: a systematic review. Transfusion. 2009;49:2442–2453. doi:10.1111/j.1537-2995.2009.02273.x
    1. Dunbar NM, Ornstein DL, Dumont L. ABO incompatible platelets: risks versus benefit. Curr Opin Hematol. 2012;19:475–479. doi:10.1097/MOH.0b013e328358b135
    1. Cooling L. ABO and platelet transfusion therapy. Immunohematology. 2007;23:20–33.
    1. Solves P, Carpio N, Balaguer A, et al. Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation. Blood Transfus. 2015;13(3):411–416. doi:10.1007/s00277-017-3168-6
    1. Stanworth SJ, Esrcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. N Engl J Med. 2013;368:1771–1780. doi:10.1056/NEJMoa1212772
    1. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusions in patients with haematological malignancies; an open-label, multicenter, randomized study. Lancet. 2012;380:1309–1313. doi:10.1016/S0140-6736(12)60689-8
    1. Stanworth SJ, Escourt IJ, Llewelyn CA, Murphy MF, Wood EM. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion. 2014;54:2385–2393. doi:10.1111/trf.12646
    1. Crighton GL, Schaefer-Eckart K, Wendelin K, et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015:CD010981. doi:10.1002/14651858.CD010981.
    1. Crighton GL, Estcourt IJ, Llewelyn CA, et al. Platelet transfusions in patients with hypoproliferative thrombocytopenia: conclusions from clinical trials and current controversies. Hematol Oncol Clin North Am. 2016;30:541–560. doi:10.1016/j.hoc.2016.01.002
    1. Malouf R, Ashraf A, Hadjinicolaoau AV, et al. Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. Cochrane Database Syst Rev. 2018;4:CD012342. doi:10.1002/14651858.CD012342
    1. Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF. Comparison of different platelet count thresholds to guide administration pf prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;11:CD010983. doi:10.1002/14651858.CD010983
    1. Estocurt LJ, Stanworth S, Doree C, et al. Different doses of prophylactic platelet transfusions for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;10:CD010984. doi:10.1002/14651858.CD010984
    1. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337(26):1870–1875. doi:10.1056/NEJM199712253372602
    1. Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood. 2017;130:1247–1258. doi:10.1182/blood-2017-01-757930
    1. Fletcher CH, DomBourian MG, Millward PA. Platelet transfusion for patients with cancer. Cancer Control. 2015;22(1):47–51. doi:10.1177/107327481502200107
    1. Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. J Vasc Interv Radiol. 2012;23(6):727–736. doi:10.1016/j.jvir.2012.02.012
    1. Shah A, Stanworth SJ, McKechnie S. Evidence and triggers for the transfusion of blood and blood products. Anaesthesia. 2015;70 Suppl 1:10–9,e3-5. doi:10.1111/anae.12893
    1. Desborough M, Hadjinicolaou AV, Chaimani A, et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. Cochrane Database Syst Rev. 2016;10:CD012055. doi:10.1002/14651858.CD012055.pub2
    1. Kerkhoffs JL, Eikenboom JC, van de Watering LM, van Wordragen-vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008;48(9):1959–1965. doi:10.1111/j.1537-2995.2008.01799.x
    1. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142:348–360. doi:10.1111/j.1365-2141.2008.07189.x
    1. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J. Factors influencing 20-hour increments after platelet transfusion. Transfusion. 1991;31(5):392–396. doi:10.1046/j.15372995.1991.31591263191.x
    1. Comont T, Tavitian S, Bardiaux L, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62–67. doi:10.1016/j.leukres.2017.08.015
    1. Solves P, Sanz J, Freiria C, et al. Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018;97(1):161–167. doi:10.1007/s00277-017-3168-6
    1. Tanoue S, Konuma T, Kato S, et al. Platelet transfusion refractoriness in single-unit cord blood transplantation for adults: risk factors and clinical outcomes. Biol Blood Marrow Transplant. 2018;24(9):1873–1880. doi:10.1016/j.bbmt.2018.05.006
    1. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106. doi:10.1182/blood-2003-08-2724
    1. Forest SK, Hod EA. Management of the platelet refractory patient. Hematol Oncol Clin N Am. 2016;30:665–677. doi:10.1016/j.hoc.2016.01.008
    1. Juskewitch JE, Norgan AP, De Goey SR, et al. How do I … manage the platelet transfusion-refractory patient? Transfusion. 2017;57(12):2828–2835. doi:10.1111/trf.14316
    1. Rioux-Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J. Utilization of cross matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion. 2014;54:3080–3087. doi:10.1111/trf.12739
    1. Yu QH, Shen YP, Ye BD, Zhou YH. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. Platelets. 2015;26:195. doi:10.3109/09537104.2013.789842
    1. Cid J, Guijarro F, Carbassé G, Lozano M. 24-h continuous infusion of platelets for patients with platelet transfusion refractoriness. Br J Haematol. 2018;181(3):386–389. doi:10.1111/bjh.14572
    1. Cid J, Magnano L, Acosta M, Alba C, Esteve J, Lozano M. Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness. Platelets. 2015;26(2):190–194. doi:10.3109/09537104.2014.895922

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe